← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oxalo Therapeutics, Inc.
Chicago, IL
$3,524,985
Total funding
3
Grants
Funding over time
peak $1.2M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,299,991 · 1
NSF$1,224,994 · 2
By mechanism
R42$2,299,991 · 1
—$1,224,994 · 2
Investigators at Oxalo Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
STTR Phase II: Developing a novel drug delivery system to enable an oral peptide-based drug for kidney stones$999,999
· FY2022 · TIP
Developing a peptide-based oral drug to prevent kidney stones$999,998
R42 · FY2019 · DK
Developing a peptide-based oral drug to prevent kidney stones$999,995
R42 · FY2020 · DK
Developing a peptide-based oral drug to prevent kidney stones$299,998
R42 · FY2018 · DK
STTR Phase I: Developing a novel drug delivery system to enable an oral peptide based drug for kidney stones$224,995
· FY2019 · TIP